Sparing Vision: How Therapies Protect Retinal Cells

Sparing vision means keeping functional sight in eyes that are already under biological attack, whether from inherited retinal disease, macular degeneration, glaucoma, or diabetic damage to the blood vessels that feed the retina. The field has expanded from a single strategy (slow the disease down) to a layered toolkit that includes gene replacement, proteins that keep dying cells alive longer, drugs that block destructive blood-vessel growth, stem-cell transplants, and even electronic chips implanted behind the retina. No single approach works for every condition, but the collective progress over the past decade has moved “vision sparing” from a hopeful phrase into measurable clinical reality for several major causes of blindness.

How the Retina Loses Its Cells

The retina is a thin sheet of neural tissue lining the back of the eye, and the cells that matter most for sight are the photoreceptors (rods and cones) and the retinal ganglion cells that relay their signals to the brain. Different diseases attack different layers. In retinitis pigmentosa (RP), genetic mutations cause rod photoreceptors to die first, which leads to night blindness. Cones then degenerate gradually after most rods are gone, eventually producing severe vision loss or complete blindness.¹ In glaucoma, the retinal ganglion cells are the primary target. Mechanical pressure, poor blood flow, and inflammatory signaling all contribute to ganglion-cell death and the axonal damage that disconnects the eye from the brain.² And in age-related macular degeneration (AMD), the disease can take two advanced forms: wet AMD, where leaky new blood vessels invade the macula and cause sudden vision loss, and geographic atrophy, where retinal pigment epithelium cells and photoreceptors slowly die across an expanding patch.³

Understanding which cells are dying, and why, is essential because every vision-sparing strategy is designed to intervene at a specific point in these chains of damage. A gene therapy that replaces a defective enzyme in pigment cells will do nothing for someone whose ganglion cells are the problem. The rest of this article walks through the major approaches, grouped roughly by the biological layer they target.

Gene Therapy for Inherited Retinal Disease

The clearest success story so far involves a gene called RPE65, which produces an enzyme critical to the visual cycle. Children born with mutations in RPE65 develop a severe form of retinal dystrophy that leads to progressive blindness. Gene therapy delivers a working copy of the gene directly beneath the retina using a harmless viral carrier. In one case study, a patient with advanced RPE65-associated RP showed sustained improvement in visual acuity, visual field, and light sensitivity three months after a single injection, with no adverse effects.⁴

Longer follow-up data tell a more nuanced story. A five-year study found that children treated with the therapy had improvement in visual acuity and visual-field testing that persisted over the full study period. Adults, however, showed less consistent gains, and those who did improve sometimes saw the benefit fade by years three through five. The data suggest that treating patients at a younger age leads to better long-term outcomes, likely because more photoreceptor cells remain alive when the corrective gene arrives.⁵ This finding carries a straightforward practical implication: for inherited retinal diseases with an available gene therapy, earlier treatment is better. Waiting for symptoms to worsen means losing cells that cannot be recovered.

A Survival Factor for Cones

In retinitis pigmentosa, the cones that provide daytime and color vision often survive for years after the rods have died, but they gradually deteriorate too. Research has identified a protein called rod-derived cone viability factor (RdCVF) that healthy rods naturally secrete to support neighboring cones. When rods die, cones lose that chemical lifeline. The idea behind RdCVF therapy is to supply the missing protein artificially and keep cones functional even after the rods are gone.

Animal studies have been encouraging. In a rat model of RP, delivering RdCVF via gene therapy slowed cone death and improved the electrical responses of cones to light.⁶ A separate experiment using direct injection of synthesized RdCVF protein into the eyes of RP rats found that cone density increased by about 20 percent compared to untreated eyes, and cone-driven electrical responses more than doubled.⁷ The protection was selective for cones; rod responses did not change, which makes sense given that RdCVF specifically supports cone metabolism. Human trials have not yet produced published results, but the animal data make a compelling case that sustaining the cone-support signal could extend useful daytime vision for years in people with RP.

Optogenetics and Making Surviving Cells See

Gene therapy for conditions like RPE65 deficiency works by fixing a broken gene while the cells it serves are still alive. But what happens when the photoreceptors themselves are already dead? Optogenetics takes a different approach: it introduces light-sensitive proteins into retinal cells that normally do not respond to light, essentially turning surviving neurons into substitute photoreceptors. Research targeting bipolar cells in the retina has shown that several optogenetic tools, including medium-wave opsin and melanopsin-based constructs, restored measurable visual acuity and contrast sensitivity in animal models with degenerated retinas.⁸

The appeal of optogenetics is that it does not depend on having any surviving photoreceptors. As long as the inner retinal circuitry and the ganglion cells that communicate with the brain are intact, light sensitivity can theoretically be restored. The resolution and dynamic range are still far short of natural vision, but for someone with no light perception, even crude image-forming ability is a dramatic change.

Anti-VEGF Drugs and the Long Game in Wet AMD

For wet age-related macular degeneration, the standard treatment is injecting drugs that block vascular endothelial growth factor (VEGF), the molecule that drives the leaky blood vessel growth responsible for acute vision loss. These injections transformed wet AMD from a near-certain path to legal blindness into a manageable condition, at least in the short term. The best visual acuity gains typically happen during the first year of treatment.⁹

The longer view is less rosy. A meta-analysis of real-world outcomes over ten years found that, on average, patients lost about eight letters of visual acuity from where they started, despite ongoing treatment. The sharpest gains came early; after that, vision gradually declined. Patients who started with worse vision and those who received more injections over the decade fared better in relative terms.¹⁰ A lifetime modeling study estimated that only about 12 percent of patients retained enough vision to drive and about 15 percent retained reading vision in at least one eye over their remaining life expectancy, with younger age at the start of treatment and more injections in the first year both predicting better outcomes.¹¹

None of this means anti-VEGF therapy is a failure. Without it, the outcomes would be dramatically worse. But it does mean that anti-VEGF alone is not a cure, and the treatment burden is significant: patients average around five to seven injections per year in the first two years, tapering to roughly four to five per year after that.¹² Consistency of treatment matters. Each additional injection during the first year was associated with a meaningful improvement in acuity, which underscores that undertreatment is a real risk, especially when patients or clinicians become fatigued by the injection schedule.

Complement Inhibitors for Geographic Atrophy

Unlike wet AMD, geographic atrophy has no abnormal blood vessels to target. Instead, the immune system’s complement pathway drives chronic inflammation that slowly kills the retinal pigment epithelium and the photoreceptors it supports. For decades there was no approved treatment. Systemic complement inhibition with drugs like eculizumab was tried but failed to slow the expansion of atrophic lesions.¹³

The breakthrough came with drugs injected directly into the eye. Pegcetacoplan, a complement C3 inhibitor, reduced the rate of geographic-atrophy growth by about 29 percent when given monthly in a phase 2 trial.¹⁴ A network meta-analysis of randomized trials confirmed that both pegcetacoplan and avacincaptad pegol significantly reduced lesion growth compared to sham injections.¹⁵ These drugs do not reverse existing damage or restore vision that has already been lost. They slow the rate at which the atrophic area expands, which in practice means buying time before the lesion encroaches on the fovea, the pinpoint center of sharpest vision.

Stem Cells and Retinal Transplants

When cells are already dead, the logical next question is whether they can be replaced. Stem-cell approaches for the retina are still largely experimental, but several lines of research have produced striking results in animals and early human trials.

On the pigment-epithelium side, transplanting strips of retinal pigment epithelium derived from donor stem cells into the eyes of patients with macular degeneration led to graft survival in all patients at one year.¹⁶ Safety testing in rodents found negligible tumor risk from these stem-cell-derived sheets over six to twelve months of monitoring.¹⁷

Replacing photoreceptors is harder because the new cells need to wire themselves into existing retinal circuits. In one study, transplanted photoreceptor precursors expressing a light-sensitive protein integrated into the retinas of blind mice and produced robust electrical responses to light.¹⁸ Transplants of lab-grown retinal sheets (organoids) into mice with end-stage degeneration formed synaptic connections with host cells and restored light sensitivity in ganglion cells to levels comparable to healthy retinas.¹⁹ Another approach used cell-sorting techniques to enrich for photoreceptor precursors before transplanting them into rats, achieving preserved retinal thickness and improved visual responses for up to twelve weeks.²⁰ These are animal results, not clinical treatments yet, but they demonstrate that newly transplanted photoreceptors can integrate, connect, and function in a degenerated retina.

Neuroprotection Through Anti-Inflammatory Signaling

Rather than replacing dead cells, neuroprotective strategies aim to slow cell death so that existing treatments and the body’s own repair mechanisms have more time to work. One area getting significant attention is the use of extracellular vesicles (tiny packets of proteins and genetic material shed by cells) derived from mesenchymal stem cells. In a mouse model of RP, these vesicles increased photoreceptor survival, preserved retinal structure, and improved visual function. The mechanism appeared to involve dampening inflammation: the vesicles suppressed the activation of immune cells in the retina and shifted the balance from pro-inflammatory to anti-inflammatory signaling.²¹ Similar vesicles have also shown protective effects in models of retinal detachment, where they reduced photoreceptor degeneration caused by separation from the supportive pigment layer.²²

In glaucoma, neurotrophic factors like BDNF and NGF have shown promise in promoting ganglion-cell survival, though results have been inconsistent. A recent review suggested that conflicting outcomes across studies may be explained by differences in when and where photoreceptor death occurs in each model: the timing and geographic pattern of degeneration seem to determine whether neurotrophic support actually reaches the cells that need it.²³ Inflammation itself plays a direct role in glaucoma-related axon damage. Tumor necrosis factor (TNF) released by glial cells can trigger optic nerve degeneration, and blocking TNF with a drug called etanercept protected axons in an animal model of high-pressure glaucoma.²⁴

Blood Pressure, Blood Sugar, and the Retinal Blood Supply

Not all vision-sparing strategies require injections or surgery. For the millions of people with diabetes, controlling blood pressure and blood sugar has a measurable impact on whether diabetic retinopathy develops. A Cochrane systematic review of eleven studies found that more intensive blood-pressure control reduced the five-year incidence of diabetic retinopathy by about 18 percent. However, once retinopathy was already established, tighter blood pressure alone did not significantly slow its progression.²⁵ A study of Chinese adults with type 2 diabetes found that neither blood pressure nor blood sugar control alone reached statistical significance for reducing retinopathy risk, but managing both simultaneously cut the likelihood of developing the condition by roughly 43 percent.²⁶

The practical takeaway is that these everyday health measures do more to protect vision when they are combined. Lowering blood pressure while blood sugar remains poorly controlled, or vice versa, may not move the needle. Getting both under control at the same time appears to produce a synergistic benefit.

Nutrition and Light Exposure

Dietary supplements have been studied extensively for AMD prevention. The large AREDS2 trial found that adding lutein and zeaxanthin to the standard supplement formula reduced progression to late AMD by about 9 percent over ten years in the overall analysis, and by about 20 percent when directly compared head-to-head against beta carotene.²⁷ Omega-3 fatty acids, however, did not show a significant benefit in the same trial’s primary analysis.²⁸ For people already at intermediate risk of AMD, lutein-zeaxanthin supplements are one of the few evidence-backed preventive measures available.

On the light-exposure side, laboratory studies have shown that blue light increases oxidative stress and cell death in retinal pigment epithelium cells, and that yellow-tinted intraocular lenses can reduce that damage.²⁹ Blue-light exposure also triggers inflammatory signaling in these cells through the NLRP3 inflammasome pathway.³⁰ Even more concerning, oxidative stress triggered in a single retinal cell can spread to its neighbors through gap junctions, amplifying the damage well beyond the initially stressed cell.³¹ These are cell-culture findings, not clinical proof that your phone screen is blinding you, but they do provide biological plausibility for why chronic high-intensity blue-light exposure could accelerate retinal aging.

Catching Damage Before You Notice It

One of the hardest problems in vision sparing is that many retinal diseases do their worst damage before the patient notices any symptoms. By the time someone with geographic atrophy or RP realizes they are losing vision, a substantial number of cells are already gone. Adaptive optics scanning laser ophthalmoscopy (AOSLO) is an imaging technology that can visualize individual photoreceptor cells in the living eye. A recent study using AOSLO found that photoreceptor reflectivity was already reduced at sites where subretinal drusenoid deposits (small lumps of debris beneath the retina associated with AMD) were forming, even before those deposits were visible on standard clinical imaging.³² Detecting trouble at that stage opens an earlier window for intervention, before standard scans would flag anything wrong.

Electronic Retinal Prostheses

When no biological cells remain to save or replace, electronic devices can bypass the retina’s light-sensing layer entirely. Retinal prostheses use a camera-equipped device to capture images and translate them into electrical signals delivered directly to the remaining retinal neurons. Recent clinical trials of subretinal photovoltaic arrays in patients with AMD achieved letter acuity matching the devices’ pixel pitch, corresponding to roughly 20/420 vision. Electronic zoom features allowed patients to read smaller text than the raw acuity would predict.³³ That level of vision will not pass a driving test, but for someone previously unable to perceive light, it can restore the ability to navigate rooms, recognize large objects, and read with magnification.

What Zebrafish Retinas Can Do

Humans cannot regenerate a damaged retina, but zebrafish can. When a zebrafish retina is injured, dormant cells called Müller glia reprogram themselves into stem-like cells that proliferate and produce new photoreceptors. Research has identified TGF-β signaling and specific matrix metalloproteinases as key regulators of this process, along with a cascade of transcription factors and microRNAs that switch on during different phases of regeneration.³⁴ Human Müller glia do not naturally do this, but they carry much of the same genetic machinery. Figuring out why the process stays locked in mammals, and whether it can be coaxed to turn on, remains one of the most tantalizing open questions in retinal science. If even partial Müller glia reprogramming became possible in human eyes, it would change the equation for every disease discussed above, replacing lost photoreceptors using cells already sitting in the patient’s own retina.